DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical trials and nonclinical stage products. It also covers the Osteoarthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Osteoarthritis Pipeline treatment landscape of the report, click here @ Osteoarthritis Pipeline Outlook

 

Key Takeaways from the Osteoarthritis Pipeline Report

• DelveInsight’s Osteoarthritis Pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis.
• The leading Osteoarthritis Companies such as Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
• Promising Osteoarthritis Therapies such as V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPA, SMC021 Oral Calcitonin, Tanezumab, acetaminophen extended release, Lorecivivint, acetaminophen, naproxen, Duloxetine, JTA-004, and others
• In May, 2023, The U.S. Food and Drug Administration (FDA) has approved LibrelaTM (bedinvetmab injectable) for the treatment of canine osteoarthritis (OA) pain, according to a press release from Zoetis Inc. (NYSE:ZTS). Librela is the first and only anti-NGF monoclonal antibody medication for canine OA pain that is administered once a month. It has been found to be both safe and successful in giving dogs with long-term relief from the symptoms of OA pain, which can enhance their mobility and general quality of life.
• In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).

 

For further information, refer to the detailed Osteoarthritis Unmet Needs, Osteoarthritis Market Drivers, and Osteoarthritis Market Barriers, click here for Osteoarthritis Ongoing Clinical Trial Analysis

 

Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected. The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints.

 

Request a sample and discover the recent advances in Osteoarthritis Ongoing Clinical Trial Analysis and Medications, click here @ Osteoarthritis Treatment Landscape

 

Osteoarthritis Emerging Drugs Profile

• Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat the patients suffering from osteoarthritis

• CYP 004: Cynata Therapeutics

Cynata’s CYP-004 MSC product is the subject of a Phase III clinical trial being sponsored by the University of Sydney and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant in addition to in-kind contributions from participating institutions. Cynata will supply Cymerus MSCs for use in the trial and will not be required to contribute any cash to fund the project. The clinical trial commenced in late 2020 and is entitled Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis (SCUlpTOR): a randomised placebo-controlled trial

• JTA-004: Bone Therapeutics

JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for the treatment of osteoarthritic pain in the knee. Consisting of a unique patented mix of plasma proteins, hyaluronic acid – a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a phase II study involving 164 patients, JTA-004 showed an improved pain relief at 3 and 6 months compared to Hylan G-F 20, the global market leader in osteoarthritis treatment.

• SMUP-IA-01: Medipost

​SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. In SMUP-IA-01’s phase I clinical trials in Korea, 12 patients with knee osteoarthritis were given a single injection into their knee joint cavity at Seoul National University Hospital. The response to the drug was then evaluated for 6 months, and the results were shown to demonstrate the safety and improvement of joint function and pain.

• TTAX03: Tissue Tech

TTAX03 is a sterile, lyophilized and micronized particulate human Amniotic and umbilical cord co product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is currently being investigated in Phase II stage of development for the treatment of patients with knee osteoarthritis.

 

Dive deep into rich insights for drugs for Osteoarthritis Market Drivers and Osteoarthritis Market Barriers, click here @ Osteoarthritis Unmet Needs and Analyst Views

 

Osteoarthritis Pipeline Therapeutics Assessment

There are approx. 130+ Osteoarthritis companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics

 

Scope of the Osteoarthritis Pipeline Report

• Coverage- Global
• Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
• Osteoarthritis Therapies- V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPA, SMC021 Oral Calcitonin, Tanezumab, acetaminophen extended release, Lorecivivint, acetaminophen, naproxen, Duloxetine, JTA-004, and others
• Osteoarthritis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Osteoarthritis Mergers and acquisitions, Osteoarthritis Licensing Activities @ Osteoarthritis Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Osteoarthritis: Overview
4. Osteoarthritis Pipeline Therapeutics
5. Osteoarthritis Therapeutic Assessment
6. Osteoarthritis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lorecivivint: Biosplice Therapeutics
9. Osteoarthritis Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. TTAX03: Tissue Tech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GLPG-0555: Gilead Sciences
15. Osteoarthritis Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Protego-PD: Plakous Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Osteoarthritis Key Companies
21. Osteoarthritis Key Products
22. Osteoarthritis- Unmet Needs
23. Osteoarthritis- Market Drivers and Barriers
24. Osteoarthritis- Future Perspectives and Conclusion
25. Osteoarthritis Analyst Views
26. Osteoarthritis Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services